Milnacipran, a well-tolerated specific serotonin and norepinephrine reuptake inhibiting antidepressant

CNS Drug Reviews

Volumn 4, Issue 2, 1998, Pages 137-148

  Briley, M ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Antidepressant; Clinical trials; Major depression; Norepinephrine reuptake; Pharmacokinetics; Serotonin reuptake

Indexed keywords

ANTIDEPRESSANT AGENT; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MILNACIPRAN; NORADRENALIN UPTAKE INHIBITOR; PLACEBO; SEROTONIN UPTAKE INHIBITOR;

CLINICAL TRIAL; DEPRESSION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG TOLERABILITY; FATIGUE; GASTROINTESTINAL TOXICITY; HUMAN; INSOMNIA; PHARMACOKINETICS; PSYCHOPHARMACOLOGY; REVIEW; SOMNOLENCE; TREMOR; VERTIGO;

EID: 0032453730     PISSN: 1080563X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3458.1998.tb00060.x     Document Type: Review

References (41)

1. Ansseau M, Von Frenckell R, Mertens C, et al. Controlled comparison of two doses of milnacipran (F2207) and amitriptyline in major depressive inpatients. Psychopharmacology 1989;98:163-168.
2. Ansseau M, Von Frenckell R, Papart P, et al. Controlled comparison of milnacipran (F2207) 200 mg and amitriptyline in endogenous depressive patients. Human Psychopharmacol 1989;4:221-227.
3. Ansseau M, Papart P, Troisfontaines B, et al. Controlled comparison of milnacipran and fluoxetine in major depression. Psychopharmacology 1994;114:131-137.
4. Assié MB, Le Lann A-D, Stenger A, Briley M. Repeated administration of milnacipran, a new antidepressant, has no effect on a functional β-adrenergic response in the rat brain. Eur J Pharmacol 1990;183:741-742.
5. Assié MB, Charveron M, Palmier C, Puozzo C, Moret C, Briley M. Effects of prolonged administration of milnacipran, a new antidepressant, on receptors and monoamine uptake in the brain of the rat. Neuropharmacology 1992;31:149-155.
6. Briley M, Prost JF, Moret C. Preclinical pharmacology of milnacipran. Int Clin Psychopharmacol 1996;11(Suppl 4):9-14.
7. Briley M. Specific serotonin and noradrenaline reuptake inhibitors (SNRIs). A review of their pharmacology, clinical efficacy, and tolerability. Human Psychopharmacol 1998;13:99-111.
8. Clerc G, Pagot R, Bouchard JM, et al. Intérêt thérapeutique du milnacipran et de la clomipramine au cours d'un traitement de 3 mois: Résultats d'un essai comparatif. Psychiatr Psychobiol 1990;5:137-434.
9. Clerc GE, Ruimy P, Verdeau Pailles J. A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. Int Clin Psychopharmacol 1994;9:139-143.
10. Danish University Antidepressant Group. Citalopram: Clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology 1986;90:131-138.
11. Danish University Antidepressant Group. Paroxetine - a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1990;18:289-299.
12. Dierick M, Ravizza L, Realini R, et al. A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients. Progr Neuropsychopharmacol Biol Psychiatry 1996;20:57-71.
13. Endo S, Miura S, Murasaki M, et al. Clinical evaluation of milnacipran hydrochloride, a new antidepressant for depression and depressive state. Phase III clinical trial with mianserine hydrochloride as a control drug. Rinsho Hyoka 1995;23:39-64.
14. European College of Neuropsychopharmacology. Clinical relevance of response and improvement in Psychopharmacology. Eur Neuropsychopharmacol 1995;5:511-533.
15. Guelfi JD, Ansseau M, Corruble E, Samuelian JC, Tournoux A, Plétan Y. A double-blind comparison of the efficacy and safety of milnacipran and fluoxetine in depressed patients. Int Clin Psychopharmacol 1998 (in press).
16. Hamilton MA Rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
17. Kasper S, Plétan Y, Solles A, Tournoux A. Comparative studies of milnacipran and tricyclic antidepressants in the treatment of patients with major depression: A summary of clinical trial results. Int Clin Psychopharmacol 1996;11(Suppl 4):35-39.
18. Ketter TA, Flockhart DA, Post RM, et al. The emerging role of cytochrome p450 3a in psychopharmacology. J Clin Psychopharmacol 1995; 15; 387-398.
19. Lacroix P, Rocher N, Gandon JM, Panconi E. Antidepressant effects of milnacipran in the learned helpless test in rats. Eur Neuropsychopharmacol 1995;5(Suppl 3):P-2-8.
20. Lecrubier Y, Pletan Y, Solles A, Tournoux A, Magne V. Clinical efficacy of milnacipran: Placebo-controlled trials. Int Clin Psychopharmacol 1996;11(Suppl 4):29-33.
21. Leinonen E, Leopola U, Mehtonen H, Rimon O-P. Long-term efficacy and safety of milnacipran compared to clomipramine in patients with major depression. Acta Psychiatr Scand 1997;96:497-504.
22. Leonard BE. The comparative pharmacology of new antidepressants. J Clin Psychiatry 1993;54(Suppl):3-17.
23. Lopez-Ibor J, Guelfi JD, Pletan Y, Tournoux, A, Prost A. Milnacipran and selective serotonin reuptake inhibitors in major depression. Int Clin Psychopharmacol 1996;11(Suppl 4):41-46.
24. Macher JP, Sichel JP, Serre C, Von Frenckell R, Huck JC, Demarez JP. Double-blind placebo-controlled study of milnacipran in hospitalized patients with major depressive disorders. Neuropsychobiology 1989;22:77-82.
25. Martensson B, Aberg-Wistedt A. The use of selective serotonin reuptake inhibitors among Swedish psychiatrists. Nord J Psychiatry 1996;50:443-450.
26. Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry 1979;134:382-329.
27. Morel C, Charveron M, Finberg JP, Couzinier JP, Briley M. Biochemical profile of midalcipran (F2207), 1-phenyl-1-diethyl-aminocarbonyl-2-aminomethyl-cyclopropane (Z) hydrochloride, a potential fourth-generation antidepressant drug. Neuropharmacology 1985;24:1211-1219.
28. Moret C, Briley M. Effect of antidepressant drugs on monoamine synthesis in brain in vivo. Neuropharmacology 1992;31:679-684.
29. Moret C, Briley M. Effects of milnacipran and pindolol on extracellular norepinephrine and serotonin levels in the guinea pig hypothalamus. J Neurochem 1997;69:815-822.
30. Mouzin G, Cousse H, Bonnaud B, et al. Derivés d'aryl-1 aminomethyl-2 cyclopropanes carboxamides (Z), leur préparation et leur application en tant que médicaments utiles dans le traitement des troubles du système nerveux centrale. French patent No. 8112312, 1981.
31. Neliat G, Bodinier MC, Panconi E, Briley M. Lack of effect of repeated administration of milnacipran, a double norepinephrine and serotonin reuptake inhibitor, on the β adrenoceptor-linked adenylate cyclase system in the rat cerebral cortex. Neuropharmacology 1996;35:589-593.
32. Nemeroff CB, Devane CL, Pollock BG. Newer antidepressants and the cytochrome P450 system. Am J Psychiatry 1996;153:311-320.
33. Puech A, Montgomery SA, Prost JF, Solles A, Briley M. Milnacipran, a new serotonin and norepinephrine reuptake inhibitor: An overview of its antidepressant activity and clinical tolerability. Int Clin Psychopharmacol 1997;12:99-108.
34. Puozzo C, Leonard BE. Pharmacokinetics of milnacipran in comparison with other antidepressants. Int Clin Psychopharmacol 1996;11(Suppl 4):15-27.
35. Puozzo C, Rostin M, Montastruc JL, Houin G. Absolute bioavailability study of midalcipran (F2207) in volunteers. In: Proceedings of the European Congress of Biopharmaceutics and Pharmacokinetics. Clermont-Ferrand, France, 1987:59-68.
36. Puozzo C, Filaquier C, Briley M. Plasma levels of F2207, a novel antidepressant, after a single oral administration in volunteers. Br J Clin Pharmacol 1985;20:291.
37. Redmond AM, Kelly JP, Leonard BE. The behavioural effects of milnacipran in the olfactory bulbectomised rat model of depression. Med Sci Res 1995;23:533-534.
38. Shaw M. New developments in antidepressant therapy. Human Pyschopharmacol 1997;12:163-165.
39. Steen A, Den Boer JA. A double-blind, six-month comparative study of milnacipran and clomipramine in major depressive disorder. Int Clin Pharmacol 1997;12:269-281.
40. Stenger A, Couzinier JP, Briley M. Psychopharmacology of midalcipran, 1-phenyl-1-diethyl-amino-carbonyl-2-aminomethylcyclopropane hydrochloride (F2207), a new potential antidepressant. Psychopharmacology 1987;91:147-153.
41. Tignol J, Pujol-Domenech J, Chartres JP, et al. Double-blind study of the efficacy and safety of milnacipran and imipramine in elderly patients with major depressive episode. Acta Psychiatr Scand. 1998;97:157-165.